PRICKLE2-AS2: A Potential Drug Target and Biomarker (G100874242)

Target Name: PRICKLE2-AS2

NCBI ID: G100874242

PRICKLE2-AS2

Other Name(s): PRICKLE2 antisense RNA 2

PRICKLE2-AS2: A Potential Drug Target and Biomarker

PRICKLE2-AS2, also known as Asparaginase, is a drug that is currently being investigated as a potential treatment for various diseases, including cancer. It is a modified asparaginase drug that is designed to be more effective and less toxic than traditional asparaginase.

Asparaginase is an enzyme that is found in many organisms, including humans. It is involved in the metabolism of asparagin, a compound that is found in many foods, including legumes, nuts, and seeds. Asparaginase is also involved in the regulation of blood clotting and is thought to have various health benefits.

PRICKLE2-AS2 is a modified form of asparaginase that is designed to be more effective and less toxic than traditional asparaginase. It is made by a genetic engineering technique called DNA-conversion, which involves introducing a gene that encodes the asparaginase enzyme into bacteria. The bacteria are then grown in a lab to produce the modified asparaginase drug.

One of the key benefits of PRICKLE2-AS2 is its reduced toxicity compared to traditional asparaginase. Traditional asparaginase can cause side effects such as nausea, vomiting, and diarrhea, as well as a drop in blood cell counts. PRICKLE2-AS2 is thought to be less toxic because it is made from a modified form of the enzyme that is less likely to cause these side effects.

Another potential benefit of PRICKLE2-AS2 is its ability to be administered directly into the bloodstream, which could make it more effective than traditional asparaginase. This is because PRICKLE2-AS2 can be more easily administered by injection or infusion, rather than through the mouth or as a pill.

PRICKLE2-AS2 is also being investigated for its potential cancer-fighting properties. It is thought to work by inhibiting the production of a protein calledasparaginase, which is involved in the development and progression of cancer. By inhibiting this protein, PRICKLE2-AS2 may be able to slow down or even reverse the growth of cancer cells.

In addition to its potential cancer-fighting properties, PRICKLE2-AS2 is also being investigated for its potential use in treating other diseases. It is being tested for its potential effectiveness in treating a variety of conditions, including pancreatic cancer, lung cancer, and amyotrophic lateral sclerosis (ALS).

While more research is needed, PRICKLE2-AS2 is an exciting new drug that is being tested for its potential in treating a variety of diseases. Its reduced toxicity and ability to be administered directly into the bloodstream make it a promising candidate for future clinical trials. As more research is done, it may be found to be a valuable tool for the treatment of cancer and other diseases.

Protein Name: PRICKLE2 Antisense RNA 2

The "PRICKLE2-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRICKLE2-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets